Separately, Maxim Group reiterated a buy rating and issued a $2.00 target price on shares of Bellerophon Therapeutics in a report on Friday, August 9th.
Shares of BLPH traded up $0.02 during mid-day trading on Monday, reaching $0.45. 122,400 shares of the company were exchanged, compared to its average volume of 249,170. Bellerophon Therapeutics has a 52 week low of $0.37 and a 52 week high of $1.22. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.64 and a current ratio of 2.64. The stock has a market capitalization of $31.64 million, a PE ratio of -1.32 and a beta of -0.05. The business has a 50 day simple moving average of $0.48 and a two-hundred day simple moving average of $0.59.
In other Bellerophon Therapeutics news, major shareholder Associates Iv L. P. Venrock sold 704,595 shares of Bellerophon Therapeutics stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $0.50, for a total value of $352,297.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Associates Iv L. P. Venrock sold 333,010 shares of Bellerophon Therapeutics stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $0.44, for a total value of $146,524.40. The disclosure for this sale can be found here. Insiders own 53.10% of the company’s stock.
A number of hedge funds have recently modified their holdings of BLPH. LPL Financial LLC increased its holdings in Bellerophon Therapeutics by 22.1% in the second quarter. LPL Financial LLC now owns 130,800 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 23,650 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Bellerophon Therapeutics by 8.9% in the second quarter. Renaissance Technologies LLC now owns 1,434,538 shares of the biotechnology company’s stock worth $860,000 after purchasing an additional 116,862 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Bellerophon Therapeutics by 15.9% in the second quarter. Vanguard Group Inc. now owns 1,152,175 shares of the biotechnology company’s stock worth $690,000 after purchasing an additional 158,000 shares in the last quarter. Institutional investors and hedge funds own 53.36% of the company’s stock.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.
Recommended Story: What is the formula for the cash asset ratio?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.